View |
|
BR-1176
|
Filgrastim
|
Topneutor
|
300 mcg/mL
|
Solution for Injection (IV/SC)
|
Immunostimulant
|
Xiamen Amoytop Biotech Co., Ltd.
|
China
|
Automatic Renewal
|
29 September 2021
|
24 August 2026
|
View |
BR-1178_PI_01.pdf
|
BR-1178
|
Insulin Degludec + Insulin Aspart
|
Ryzodeg FlexTouch
|
100 Units/mL (70% Insulin Degludec/30% Insulin
Aspart)
|
Solution for Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
Initial (from Monitored Release)
|
12 January 2023
|
30 September 2026
|
View |
|
BR-1179
|
Lactobacillus gasseri + Lactobacillus rhamnosus
|
Ecovag
|
Formulation: Each hard vaginal capsule contains: Lactobacillus gasseri EB01 strain........Min. 10^8 cfu Lactobacillus rhamnosus PB01 strain..........Min. 10^8 cfu
|
Hard Vaginal Capsule
|
Anti-infectives/Antiseptics
|
Deerland Priobiotics & Enzymes A/S
|
Denmark
|
-
|
18 March 2022
|
20 September 2026
|
View |
|
BR-1180
|
Filgrastim
|
Macroleuco
|
150 mcg/0.6 mL
|
Solution for Injection (IV/SC)
|
-
|
Dong-A ST Co., Ltd.
|
Korea
|
Initial (Variation)
|
07 November 2023
|
07 November 2028
|
View |
|
BR-1181
|
Filgrastim
|
Macroleuco
|
300 mcg/1.2 mL
|
Solution for Injection (IV/SC)
|
-
|
Dong-A ST Co., Ltd.
|
Korea
|
Initial (Variation)
|
07 November 2023
|
07 November 2028
|
View |
|
BR-1182
|
Heparin Sodium
|
Aprinol 25000
|
5000IU/mL (25000IU/5mL)
|
Solution For Injection (IV/SC)
|
-
|
U-Square Lifesciences Pvt. Ltd.
|
India
|
-
|
16 March 2022
|
26 September 2026
|
View |
|
BR-1183
|
Heparin Sodium
|
Aprinol 5000
|
1000IU/mL (5000IU/5mL)
|
Solution For Injection (IV/SC)
|
-
|
U-Square Lifesciences Pvt. Ltd.
|
India
|
-
|
16 March 2022
|
26 September 2026
|
View |
|
BR-1184
|
Follitropin Alfa / Lutropin Alfa
|
Pergoveris
|
150 IU / 75 IU
|
Powder for Solution for Injection (SC)
|
-
|
Merck Serono S.A.
|
Switzerland
|
Renewal (Re-issuance)
|
02 September 2022
|
01 July 2026
|
View |
|
BR-1186
|
Human Coagulation Factor VIII
|
Octanate
|
250 IU
|
Powder for Solution for Intravenous Injection
|
Plasma Fractions for Specific Use
|
Octapharma AB
|
Sweden
|
Automatic Renewal
|
14 October 2021
|
11 November 2026
|
View |
|
BR-1187
|
Human Coagulation Factor VIII
|
Octanate
|
1000 IU
|
Powder for Solution for Intravenous Injection
|
Plasma Fractions for Specific Use
|
Octapharma AB
|
Sweden
|
Automatic Renewal
|
26 October 2021
|
11 November 2026
|
View |
|
BR-1188
|
Alteplase
|
Actilyse
|
20 mg
|
Powder for Solution for Infusion (IV)
|
-
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
Initial (Variation)
|
02 September 2022
|
02 September 2027
|
View |
|
BR-1189
|
Insulin aspart
|
NovoRapid Flex Touch
|
100 IU/mL
|
Solution for Injection (SC/IV)
|
Antidiabetic
|
Novo Nordisk A/S
|
Denmark
|
Renewal
|
23 May 2022
|
24 October 2026
|
View |
|
BR-1195
|
Filgrastim
|
Filgen
|
300 mcg/mL
|
Solution for Injection (IV/SC)
|
IMMUNOSTIMULANT
|
BF Biosciences Limited
|
Pakistan
|
Renewal
|
27 September 2021
|
04 October 2026
|
View |
|
BR-1196
|
Affinity-Purified Antibodies To Human Interferon Gamma
|
Anaferon
|
3 mg
|
Orodispersible Tablet
|
-
|
“NPF” Materia Medica Holding
|
Russia
|
-
|
07 March 2022
|
22 November 2026
|
View |
|
BR-1197
|
Menotrophin
|
Menopur
|
600 IU
|
Powder for Solution for Injection (SC)
|
-
|
Ferring GmbH
|
Germany
|
-
|
09 February 2022
|
07 December 2026
|
View |
|
BR-1198
|
Filgrastim
|
Zarzio
|
30 MU/0.5mL
|
Solution For Injection/Infusion (SC/IV)
|
-
|
Sandoz GmbH - Betriebsstätie / Manufacíuring Site
|
Austria
|
-
|
15 March 2022
|
15 December 2026
|
View |
|
BR-1199
|
Clostridium Botulinum Type A Neurotoxin complex
|
Botox
|
50 Units
|
Powder for Solution for Injection (IM)
|
-
|
Allergan Pharmaceuticals Ireland
|
Ireland
|
-
|
16 March 2022
|
13 January 2027
|
View |
|
BR-1207
|
Vedolizumab
|
Entyvio
|
300 mg
|
Powder for Concentrate for Solution for
Infusion (IV)
|
-
|
Takeda Pharmaceutical Company Limited (Hikari Plant)
|
Japan
|
Initial [from Monitored Release] (Reconstruction)
|
16 January 2024
|
24 February 2027
|
View |
|
BR-1210
|
Idarucizumab
|
Praxbind
|
50mg/mL
|
Solution For Injection (IV)
|
-
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
-
|
22 April 2022
|
13 March 2027
|
View |
|
BR-1214
|
Human Papillomavirus 9-Valent Vaccine (Recombinant,
Adsorbed)
|
Gardasil 9
|
Formulation: Each dose (0.5 mL) contains:
Human Papillomavirus Type 6 1.1-30 mcg protein Human Papillomavirus Type 11 1.1 protein-40 mcg
Human Papillomavirus Type 16 1.1 protein-60 mcg Human Papillomavirus Type 18 1.1 protein-40 mcg
Human Papillomavirus Type 31 1.1 protein-20 mcg
Human Papillomavirus Type 33 1.1 protein -20 mcg
Human Papillomavirus Type 45 1.1 protein -20 mcg
Human Papillomavirus Type 52 1.1 protein-20 mcg Human Papillomavirus Type 58 1.1 protein-20 mcg
Adsorbed on amorphous aluminum hydroxyphosphate sulphate adjuvant (500 mcg Al)
|
Suspension for Injection (IM)
|
-
|
Merck Sharp & Dohme Corporation
|
United States of America
|
Initial (from Monitored Release)
|
05 August 2022
|
04 April 2027
|